Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials Reply

被引：2
|
作者：
Sidharthan, Sreetha [1 ]
Kohli, Anita [1 ]
Kottilil, Shyam [2 ,3 ]
机构：
[1] NIH, Crit Care Med Dept, Natl Inst Hlth Clin Ctr, Bethesda, MD 20892 USA
[2] Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA
[3] NIH, Lab Immunoregulat, Natl Inst Allergy & Infect Dis, Bethesda, MD 20892 USA
来源：
CLINICAL INFECTIOUS DISEASES | 2015年 / 61卷 / 04期
关键词：
GENOTYPE; 1; INFECTION; RIBAVIRIN;
D O I：
10.1093/cid/civ403
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：667 / 668
页数：3
相关论文
共 50 条
  • [1] Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials
    Harrington, Patrick R.
    Deming, Damon J.
    Komatsu, Takashi E.
    Naeger, Lisa K.
    CLINICAL INFECTIOUS DISEASES, 2015, 61 (04) : 666 - 667
  • [2] Electrocardiographic alterations during interferon-free direct-acting antiviral therapy for hepatitis C virus
    Garcia-Arribas, D.
    Lopez-Garcia, O. N.
    Olmos, C.
    Higueras Nafria, J.
    Devesa Medina, M. J.
    Cuenca Alarcon, F.
    Izquierdo Rubio, S.
    Maroto Castellanos, M.
    Rey Diaz-Rubio, E.
    EUROPEAN HEART JOURNAL, 2017, 38 : 578 - 578
  • [3] Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
    Pawlotsky, Jean-Michel
    GASTROENTEROLOGY, 2016, 151 (01) : 70 - 86
  • [4] Interferon-free, direct-acting antiviral therapy for chronic hepatitis C
    Gutierrez, J. A.
    Lawitz, E. J.
    Poordad, F.
    JOURNAL OF VIRAL HEPATITIS, 2015, 22 (11) : 861 - 870
  • [5] Interferon-free direct-acting antiviral (DAA) regimens for treatment of chronic hepatitis C
    Kowdley, K.
    JOURNAL OF VIRAL HEPATITIS, 2014, 21 : 9 - 9
  • [6] Impact of Obesity on Treatment of Chronic Hepatitis C in Interferon-Free Direct-Acting Antiviral Era
    KyDieu Tran
    Kuwajima, Vanessa K.
    Tahan, Veysel
    HEPATOLOGY, 2018, 68 : 404A - 404A
  • [7] Prevalence and risk factors of hepatitis B virus reactivation in interferon-free direct-acting antiviral therapies for hepatitis C
    Kawagishi, N.
    Suda, G.
    Onozawa, M.
    Kimura, M.
    Maehara, O.
    Ohara, M.
    Izumi, T.
    Umemura, M.
    Ito, J.
    Nakai, M.
    Sho, T.
    Natsuizka, M.
    Morikawa, K.
    Ogawa, K.
    Sakamoto, N.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S725 - S726
  • [8] Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection
    Gray, E.
    O'Leary, A.
    Kieran, J. A.
    Fogarty, E.
    Dowling, T.
    Norris, S.
    JOURNAL OF VIRAL HEPATITIS, 2016, 23 (09) : 677 - 686
  • [9] Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection
    Liu, Chen-Hua
    Liu, Chun-Jen
    Su, Tung-Hung
    Fang, Yu-Jen
    Yang, Hung-Chih
    Chen, Pei-Jer
    Chen, Ding-Shinn
    Kao, Jia-Horng
    OPEN FORUM INFECTIOUS DISEASES, 2017, 4 (01):
  • [10] All Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C
    Shahid, Imran
    Ibrahim, Munjed M.
    CURRENT MOLECULAR MEDICINE, 2018, 18 (07) : 409 - 435
12345